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Chronic neurological diseases are the leading source of disability globally. Yet, our healthcare systems are 
not designed optimally to meet the needs of the many chronic neurological patients. Care is fragmented, 
with poor interdisciplinary collaboration and lack of timely access to services and therapies. Furthermore, 
care is typically reactive, and complex problems are managed inadequately due to lack of disease-specific 
expertise and insufficient use of non-pharmacological interventions. Treatment plans tend to focus on the 
disease rather than the individual living with it, and patients are insufficiently involved in clinical decision 
making. Utilising Parkinson’s disease as a model condition, we illustrate an integrated care concept with a 
patient-centred perspective that includes evidence-based solutions to tackle the limitations of current 
healthcare delivery for people with chronic neurological conditions. We anticipate that this integrated 
care model will improve the quality of lives of patients and create an attractive working environment for 



















Search strategy and selection criteria 
We searched for publications on healthcare and neurological conditions (in particular Parkinson’s disease) 
published in MEDLINE from 1 January 1990 to 28 January 2020, using comprehensive electronic search 
strategies combining MeSH and free text search terms “chronic”, “care”, “network”, “patient-
centeredness”, “integrated”, “multidisciplinary”, “interdisciplinary”, “technology”, “health services”, 
“wearable sensors”, “telemedicine”, “Parkinson disease” and “Parkinson’s disease”, without language 
restrictions. Selected articles were also obtained from the reference lists of papers identified by the 





Chronic neurological conditions are now the leading source of disability globally.1 Because of a rapidly 
expanding ageing population, the worldwide prevalence and burden of chronic neurological diseases will 
rise further in the coming decades. To meet the needs of these many chronic neurological patients, an 
optimally performing healthcare system should reach the Quadruple Aim: enhancing patient experience, 
improving population health, reducing costs (these originally formed the Triple Aim)2 and improving the 
work-life of clinicians.3 However, recognition grows that our current healthcare system is not designed 
optimally to reach this Quadruple Aim. Indeed, the patient experience is far from optimal,4 patients 
sustain avoidable disability, healthcare costs rise sharply and many clinicians face dissatisfaction or 
burnout.5 Here, we review the challenges that current neurology care poses to patients, and introduce 
possible evidence-based solutions. We discuss how these solutions may be combined within a model of 
integrated care, which is defined as health services that are managed, discussed and delivered so that 
patients can make various health- and disease-related choices according to their needs throughout the life 
course.6 This integrated model takes a patient-centred approach and would be tailored around helping 
chronic neurological patients to minimize the impact of their disease, and assists them in living 
independently at home, aiming to prevent escalation to more expensive institutionalised care (Figure 1). 
We illustrate our vision by using Parkinson’s disease (PD) as a “model condition” for many other chronic 
neurological disorders (Panel 1), assuming that any successes obtained by improving the care for people 
with PD may be extended to other chronic neurological disorders. The model mostly entails solutions that 
are universally applicable (i.e. across a wide range of different chronic disorders) and that are at present 
largely restricted to specific health systems, such as middle- or high-income countries or public insurance-
based healthcare systems. 
 
Challenges and solutions for healthcare  
Several barriers in today’s healthcare hamper us from reaching the Quadruple Aim (Supplement A). We 
next discuss some solutions that can help to make care better equipped to overcome these barriers (Panel 
2).  
  
Care delivery close to home  
Currently, chronic neurology care is delivered mainly in hospitals that are designed primarily for patients 
with acute diseases. Accessibility is limited for those living at greater distances.57 Furthermore, medical 
decisions are based almost exclusively on periodic in-clinic evaluations, but such “snapshots” cannot 
capture the actual impact on the patient’s functioning in their own home environment. An important aim 
is therefore to migrate neurological care away from medical centres, back into the patient’s own home 
environment.57 Being able to monitor and treat people at home is not only a service to patients, but also 
leads to more relevant insights, better care, and lower cost. Consequently, a patient’s home could be 
considered a “Homespital” where some tasks currently performed within hospitals could be 
implemented.58 We consider two important developments: first, the importance of assessing patients 
during their normal activities and functions; second, the value of delivering interventions as close to home 
as possible. New developments in the field of digitised health will be greatly supportive here (Supplement 
B). Remote monitoring can help to obviate unnecessary routine consultations among those doing well, 
while helping to identify those patients requiring medical attention. When care is required, the default 





Patient empowerment and self-management 
Patients demand more empowerment than they currently receive. Against their wishes,4,59 most patients 
are not well-informed about PD and are not counselled adequately to cope with the consequences. 
Therefore, a second goal is to shift from paternalistic care–led by healthcare professionals–to 
“participatory health”, with equality in attitude towards complementary contributions of patients, carers 
and professionals. The focus should be on self-management by well-informed, empowered patients, with 
involvement of professional support when needed. The premise is that empowered patients will be less 
anxious, experience a better quality of life and are less likely to seek medical support, thus helping to 
reduce healthcare costs. This development fits with a new definition of “health”, which is no longer 
described as the complete absence of any physical, mental or social unwell being, but rather as the ability 
to adapt and self-manage.22 
 
Patients can be empowered in various ways (Panel 2). Adequate patient counselling is essential, yet 
patients generally feel uninformed.4,59 Patient education must extend beyond information about the 
neurological condition or its management, and lifestyle advice should be part of counselling by healthcare 
professionals, irrespective of the health system they work in. 
 
An important part of patient empowerment is introducing tools for shared decision making, allowing 
patients and carers to participate in making optimal treatment decisions, tailored to their specific 
situation. Formal procedures exist to develop validated shared decision tools, allowing patients to make 
weighed decisions based on reliable information about e.g. treatment effects or risk of adverse effects. 
Shared decision tools are already available for several key choices in PD management (Panel 2). Both 
patient and clinicians feel that use of Patient Reported Outcome Measures (PROMS) can help to support 
the shared decision process during consultations, although patients may need training to interpret the 
information correctly.60 Involving patients in developing these instruments boosts face validity and 
increases their potential to reflect outcomes that are important to patients.61 Achieving shared decision 
making should be a universal priority among healthcare professionals. However, much work remains to be 
done: a European survey indicated that many persons with PD feel insufficiently involved when it comes 
to making important treatment decisions.62  
 
Patient empowerment also implies caring for the individual’s entire environment, with specific emphasis 
on immediate carers. Caring for people with PD is associated with high burden, negatively impacts well-
being and is associated with depression63 and increased mortality risk.64 Other psychological impacts 
include social isolation, loss of self-identity, feelings of helplessness and lack of control.65 Carers often 
have their own healthcare needs and this, coupled with the physical and economic burden of caring, 
frequently precipitates inpatient admissions for patients who can no longer be cared for at home. Taken 
together, this is ample reason to consider not just the patient, but also the immediate carers.  
 
Proactive and timely care 
Current care is mainly reactive, focusing on tackling problems when they arise. This causes unnecessary 
burden for patients and leads to costly hospital admissions, many of which seem preventable. Optimal 
care involves not just responding to problems expressed by patients, but also adopting a proactive 
approach, aiming to detect early warning signs that may herald the onset of more debilitating (and costly) 
problems. Persons with PD are more likely to be admitted than their peers, disease progression being 
associated with unplanned hospital admissions.66,67 Early recognition of patients at risk of admission 
 
 6 
affords an opportunity to intervene. One example is timely detection of near-falls, which typically precede 
the onset of falls and fall-related injuries–the latter being a major cost driver in Parkinson care.68 Rather 
than waiting for injuries to occur, preventive measures can be taken, including medication adjustments, 
specialized physiotherapy, and optimization of the home environment to minimize the risk of falling.69 
 
Proactive care becomes increasingly relevant in older patients with PD with neuropsychiatric 
manifestations, including apathy or dementia, who are not well-positioned to assume a proactive role 
themselves. Case management serves a critical function to proactively identify these vulnerable patients. 
This may pre-emptively optimise their physiology and environment to minimise the risk of avoidable 
complications and prevent admission to hospital and care facilities. Yet, a reality is that hospital visits for 
complex patients can never be fully prevented.66 67As inpatients, they have a longer length of stay than 
age-matched controls, with more deconditioning, loss of confidence and exposure to iatrogenic risks (such 
as hospital-related infection). They are also less likely to return to their normal place of residence and to 
have higher in-hospital mortality.70 Delays in receiving ‘medication on time’ can further exacerbate 
problems of reduced mobility, swallowing difficulty and falls. Inpatient care should therefore be optimised 
to minimise the risk of these complications, including education of ward nurses on the importance of 
‘medication on time’. Specific measures include early PD specialist review to optimise medication, also for 
admissions to general wards.71,72 This process should be supported by early flagging in electronic medical 
records, to alert a dedicated inpatient team that someone with PD has been admitted. Unpublished 
experience at Struthers Parkinson’s Centre in the U.S. shows that such electronic flagging can markedly 
improve the timing of levodopa administrations and minimize missed doses in the hospital and emergency 
centre (Nance M. & Wielinski C., personal communication). This example illustrates how proactive 
screening can be facilitated by developments in digital health (Supplement B). Digital health could 
improve the quality of care, and potentially save costs, e.g. because proactive monitoring can prevent 
complications. However, the evidence for this remains limited, also when it comes to demonstrating 
beneficial effects on patient outcomes.  
 
Precision medicine 
Current treatments typically follow a “one-size-fits-all” approach, but there is an urgent need for 
development of personalised “precision” approaches, with care tailored to each patient’s unique profile 
and personal needs. Therefore, a further key element is delivery of care according to each patient’s 
unique sociodemographic, disease-specific and genetic factors, considered in tandem with their personal 
objectives and goals. Current scientific evidence, especially insights derived from controlled clinical trials, 
is imperfect in this regard, because the insights are based on relatively small and often selected study 
populations, with brief follow-up periods, making it difficult to translate the outcome to the care for 
individual patients in everyday practice. This applies particularly to specific underserved subgroups, 
caused by issues related to age,73 gender,26,74 racial27-30 or cultural differences.31,32  
 
Realisation of personalised medicine will greatly benefit from developments in the fields of “big data” and 
artificial intelligence,40,41 where insights derived from much larger and unselected real-life populations, or 
from smaller groups of deeply phenotyped patients, can lead to development of fine-grained personal 
disease profiles that better represent the full complexity of individual patients. Such knowledge will allow 
clinicians to offer patients more detailed prognostic information based on personalized profiling, and to 
tailor their treatment advice to the unique profiles of their patients, which is particularly important for a 
disorder characterized by significant heterogeneity like PD.42 The first positive experiences in the PD field 
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are emerging, mainly in establishing more refined prognosticators for specific endpoints at the group 
level, but reliable individual predictors have yet to be identified.75-80 Importantly, big data approaches do 
not intend to replace existing information resources, but can rather act as a fourth and complimentary 
source of information in clinical decision making, next to scientific evidence, professional expertise, and 
the personal needs and preferences of patients. Combining the strength of all four information sources 
then leads to a process of ‘quadruple decision making’.81 
 
Specialist care and professional training  
Management of chronic neurological conditions like PD has transformed into a complex, highly specialised 
field of medicine, calling for expert skills to ensure that patients receive optimal care, in accordance with 
the latest scientific evidence. Such specialised professionals are more likely to adhere to professional 
guidelines, and are better aware of what fellow professionals can contribute to care.44 Trainings are 
delivered best to multidisciplinary teams, which improves PD-specific knowledge and leads to a better 
understanding of the role of other disciplines.46 Allocating care preferentially to allied health professionals 
who have specialised in PD management is associated with better patient outcomes and lower costs in the 
Netherlands (ParkinsonNet model of care–Panel 3).45,82 There are also successful examples in other areas 
of neurology and other fields of medicine, where specialisation was associated with better care, better 
patient health and cost savings.83,84 Medical societies should always be involved in ascertaining the quality 
and nationwide implementation of the educational programs. For example, all training programs 
delivered by ParkinsonNet are done according to guidelines that have been ratified by the corresponding 
national medical societies. The Dutch experience indicates that the costs of such educational programs are 
offset by subsequent cost savings.44 
 
Professional training may further help improve the quality of care for persons with PD in nursing homes, 
where both undertreatment with Parkinson medication and overtreatment with sedatives are common.85 
Another area of largely unmet need relates to end-of-life issues and palliative care interventions, which 
are traditionally equated with cancer management. Persons with PD also experience moderate palliative 
care needs,86 but palliation is presently unavailable for most patients.50,51 Recent work demonstrated that 
a one-year multidisciplinary palliative care program improved quality of life for patients with moderate 
palliative care needs,87 emphasising the importance of training professionals to recognise and manage 
palliative care needs as part of integrated PD management.88 
 
Finally, professional training may help to create a positive healthcare engagement for professionals, and 
enhance their experience of delivering care. Complex and debilitating neurological conditions such as PD 
can be alarming to inexperienced clinicians, but can be gratifying when their knowledge is adequate, and 
when clinicians accumulate greater experience by managing a high case load of patients with comparable 
health issues.89 Enhancing the work-life of clinicians thus helps to achieve the Quadruple Aim by reducing 
burnout,3 and possibly by motivating students to opt for a future career in medicine. 
 
Care management 
Current care is fragmented across different healthcare providers and organisations, leading to a waste of 
resources. Unsurprisingly, people with PD–when asked to identify their top priorities for healthcare 
improvement–identify access to a single point of access (personal care manager) as their most urgent 
need.4 The personal care manager can act as a single point of access who can immediately answer 
questions, or triage the issue accordingly.4 It is neither feasible nor cost-effective to place the movement 
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disorder specialist in this role. The reality is that there is already a shortage of specialist clinicians for a 
fast-growing Parkinson population.7,90 Consequently, waiting lists are long, and movement disorder 
specialists have limited time to see their patients. The Parkinson nurse is an excellent candidate to fulfil 
this role of being the first point of access for patient queries, with several specific tasks: triage, dedicated 
referral, and care coordination (Supplement C). Nurses in this role may be based in community hospitals–
acting as a personal care manager–but in less densely populated areas, nurses could also deliver services 
from a remote service desk (telephone call centre), acting as telehealth assistants. Such a model is 
recommended and partially in place in the UK,52 although many areas lack sufficient numbers of 
specialised nurses to deliver ready access to all patients, and to fully adopt the role as personal care 
manager. 
 
An important part of care coordination is to establish links between PD-specialists and generalists working 
in the community, including general practitioners who are optimally positioned to manage comorbidities 
and polypharmacy within the wider social context, in relation to the domestic situation.53 Increasing PD-
specific knowledge amongst general practitioners will augment their confidence in caring for patients with 
complex neurological illnesses and strengthen collaborative links with movement disorder specialists.53 To 
achieve this, general practitioners should be provided with easy access to a specialised network 
professional when in need of referral for a PD-specific health issue. Furthermore, general neurologists 
working in community hospitals can deliver higher-quality care for people with PD when supported by a 
remote PD-expert via telemedicine (peer-to-peer consultations). This approach previously contributed to 
more accurate clinical decision making in the field of acute stroke treatment.54  
 
Delivery of integrated care 
Each of the aforementioned solutions, when delivered in isolation, will help to improve the quality of care 
for patients with neurological illnesses. However, we anticipate that care delivery can be optimised 
further by seamlessly connecting the layers of healthcare and bundling all solutions into an integrated 
network, across both professional disciplines and different healthcare settings.56 Such an integrated model 
is referred to as population health management, where responsibility is taken for an entire specific 
population, including cross-sector collaboration, coordination with community services (also the social 
domain, e.g. ascertaining adequate housing circumstances) and non-clinical interventions (e.g. healthier 
lifestyle).2,91 There is some initial evidence to suggest that this approach leads to better outcomes, while 
overall healthcare spending remains the same.91 
 
A “home-hub-and-spoke” model is one way of structuring care services for a whole population (Figure 2). 
The patient’s own home represents the first of three constituents; efforts directed here include patient 
education, promotion of self-management, and home-based monitoring. The movement disorder 
specialist in a community hospital, combined with specialised allied health professionals in the regional 
community, jointly form the second constituent (“spoke”). Many services can be offered here. The role of 
the third part–an academic “hub”–is not in physically seeing many patients, but in adding value to the 
entire network, e.g. via peer-to-peer support for multiple spokes, educating patients and professionals, 
guideline development, and research. This hub may be located geographically close to its surrounding 





The need for integrated care increases when advanced and likely expensive new treatments become 
available, such as pharmacological and non-pharmacological disease-modifying strategies. In these 
situations, considerable PD-specific knowledge is required for optimal decision making. In the proposed 
model, regional movement disorders specialists would have a critical role in informing decisions, 
supported where necessary by expertise and infrastructure at the hub (peer-to-peer expertise via 
telemedicine would be appropriate for this). Such remote hub support could also support the diagnostic 
process (review of videotaped neurological exams), because the rate of diagnostic misclassification in 
early disease stages is higher among generalists than among experts.92 
 
The experience with integrated care is thus far not unequivocally positive, although most studies suggest 
that reductions in hospital (re-)admissions and emergency department visits can be achieved.56 Further 
work is now needed to demonstrate the actual value of integrated care for patients with neurological 
diseases. Additional research is also warranted on the implementation of the model in conditions where 
cognition is significantly affected, such as Alzheimer’s disease or other primary dementias. 
 
Financial considerations 
The primary aim of integrated care should be an improved quality of life for patients with chronic 
neurological conditions, and a better population health. Cost containment is not a purpose in its own 
right,91 although integrated care might reduce costs, which is one component of the Quadruple Aim 
(Figure 1).3 Cost savings may result from greater efficiency of care, prevented disease complications and 
reductions in unplanned hospital admissions (Panel 4), although any cost savings are potentially offset by 
the necessary upfront investments in quality of integrated care.91 
 
There is some evidence in the field of PD to support these assumptions. For example, various studies 
showed that professional specialisation, improved interdisciplinary collaboration and patient education–
as achieved via the Dutch ParkinsonNet approach (Panel 3)–leads to considerable cost savings, via greater 
efficiency of care (specialised therapists provide substantially less treatment sessions) and fewer disease 
complications (injuries or pneumonia).43-45,47 Taking the most conservative cost saving of $439 per 
patient,93 the savings equated to around 5% of the expenditure on chronic Parkinson care in The 
Netherlands (about 20-30 million euros annually). It is conceivable that adding further elements to this 
approach–e.g. personalized care management–will lead to even greater cost savings. As such, integrated 
care models can help to ascertain an affordable care system for our future generations. Importantly, while 
this model for network-based allied healthcare was originally developed in The Netherlands, which has a 
public insurance-based healthcare system, it has subsequently been successfully transferred in healthcare 
systems that had a different infrastructure (e.g., Kaiser Permanente, an accountable care organisation in 
California).94 We note that translation of this model and its possible implications for cost savings requires 
further study in other healthcare systems. 
 
Challenges in rural and low-resource settings  
Four decades after the WHO declared ‘health for all’ by the year 2000, international and even regional 
differences in quality of care for patients with chronic diseases remain stark. We realize that 
implementing an integrated model of care, or even elements thereof, will pose tremendous challenges in 
sparsely populated or economically less developed areas of the world. We therefore anticipate that the 
network by which integrated care is delivered will depend on local, regional or national circumstances, 
including the geographical spread of the population across urban and rural areas, and on physical 
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distances. In countries where healthcare delivery for people with PD is largely hospital-based or delivered 
across substantial distances, care models must be adapted. For example, introduction of network care in 
California pursued the concept of specialised professional education, but not for allied health therapists 
working in the community–as was feasibly done in a densely populated country such as the Netherlands–
but rather by training hospital-based teams.94 This approach, although different, also resulted in the 
desired concentration of care among specifically trained professionals,94 which is a subsidiary 
intermediate for achieving good outcomes.44  
 
The current and future provision of Parkinson’s nurses, movement disorder specialists and 
multidisciplinary expertise will also impact on care structures. In countries such as the UK and the 
Netherlands, where the Parkinson’s nurse specialist role is well-established and successful, nurses are 
based in both community and secondary care settings. However, most Parkinson’s nurses in these 
countries work closely with movement disorder specialists who treat the same people with PD, suggesting 
that transference of this model may be challenging to countries where patients lack regular follow-up by a 
movement disorder specialist. For example, 33% of people with PD in the U.S. do not receive regular 
neurologist care, let alone movement disorder specialist care.29 
 
Challenges will be even greater in in economically less developed areas of the world (Supplement D). 
Here, barriers relate to human resources (e.g. lack of sufficiently trained healthcare professionals), 
financial factors and cultural differences in leadership or accountability.95 In many countries worldwide, 
numerous patients remain undiagnosed,96 while essential medication such as levodopa is either poorly 
available or, even when offered, unaffordable for many.31 Furthermore, people from several large regions 
(e.g. the Western Pacific) are underrepresented in healthcare innovation research, despite substantial 
variability in the clinical presentation and comorbidity profiles of PD patients across the world.97 The role 
of telemedicine will become particularly important in combatting these challenges in both clinical care 
and research. In countries such as China, readily available app programs on mobile phones are already 
widely used among medical professional and patients for communication or consultations. A 
complimentary strategy would be to ensure that healthcare professionals in low-resource settings receive 
clinical decision support algorithms covering evidence-informed care. In the area of communicable 
diseases, this strategy substantially improved measures of population health, quality of care and effective 
use of healthcare services.95  
 
Conclusions and future perspectives 
Using PD as an exemplar condition, we have illustrated a model of care for patients with neurological 
conditions, including a patient-centred and proactive approach embedded within integrated networks 
where specifically trained professionals from multiple disciplines collaborate effectively (panel 5). We 
foresee an increasingly prominent and recognised role for specialised nurses, acting as personal care 
managers for individual patients and as care coordinators for the network. Part of this vision is supported 
by empirical evidence, albeit mainly for the separate components of the integrated approach. There are 
also striking lacunae in our knowledge, such as lack of scientific underpinning for the roles of Parkinson 
nurses. Future work must therefore gather further evidence, both for all separate components and their 
integration. A challenge here is that evaluations of such complex interventions require a spectrum of 
approaches to provide robust evidence. Alongside randomised clinical trials, this could include additional 
methodologies such as observational studies with analyses of medical claims data–comparing regions with 




While most solutions proposed in the model could be readily implemented across various health systems 
and patient groups, including those in low-resource settings or areas where distances are substantial, 
other solutions may not be universally applicable. In particular, the feasibility of leveraging novel 
technological developments may in the near future be limited to high- and middle-income countries. 
Beyond the very short-term, however, technological developments may also become available to people 
with PD in low-income countries, given the remarkable recent rise in smartphone ownership across 
impoverished regions; e.g., in Sub-Saharan Africa, smartphone ownership rose from 15% in 2014 to 33% in 
2017.102 
 
We anticipate that patients with other chronic and complex progressive neurological conditions like 
dystonia or neuromuscular diseases, or those with a more paroxysmal or fluctuating character like 
epilepsy or relapsing-remitting multiple sclerosis, also deserve an approach of networked care with a 
patient-centred, proactive methodology delivered by specialised professionals treating a high case load. 
Modifications in care delivery may be required, depending on the nature and prevalence of each condition 
and on specific patient needs. For example, considerably fewer professionals have to be trained for rare 
disorders such as Huntington disease, so concentration of expertise within a limited number of expert 
centres makes sense, in contrast to PD where community-based networks seem effective. The knowledge 
in some of these areas of neurology is growing, as exemplified by positive experiences with network care 
for e.g. patients with Alzheimer disease.9 A key point will be to learn from contrasts between different 
networks, so the best of all worlds can be synthesised into an optimised care model. From a population 
health management perspective, it might be beneficial to concentrate expertise around a number of 
comparable chronic progressive neurological disorders within bundled specialised networks, which are 
characterized by a patient-centred, proactive methodology delivered by specialised professionals treating 
a high case load of comparable chronic progressive neurological disorders, including selected outreach 
clinics with connection to hubs specializing in each of the subspecialty areas. Bundled specialised 
networks include selected outreach clinics with connection to hubs specializing in each of the subspecialty 
areas. We anticipate that research on bundled specialised networks will rapidly increase in the next years. 
We therefore extend an open invitation to colleagues from other fields to share their experiences, so that 
all our patients can benefit. 
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Panel 1. Parkinson’s disease as a model condition. 
 
We regard Parkinson’s disease as an ideal “model condition” for many other chronic neurological 
disorders, for various reasons: (a) the clinical phenotype encompasses a wide range of motor as well as 
non-motor features, including cognitive decline, autonomic failure and neuropsychiatric features; (b) 
optimal Parkinson care requires involvement of multiple (over 20 different) professional disciplines, who 
work in different healthcare settings, including the community, regional hospitals and specialised clinics; 
(c) management is multimodal, involving complex pharmacotherapy, neurosurgical procedures, and 
various non-pharmacological interventions; (d) the disease duration is long, spanning up to decades for 
affected patients, plus a presumably lengthy prodromal phase; and (e) the disease is common, with an 




Panel 2. Challenges and suggested solutions to improve the management of patients with chronic 
neurological conditions like PD. For each proposed solution, we provide supportive evidence, capitalizing 
not only on the experience in the field of PD, but also on knowledge obtained for other conditions such as 
dementia8,9 and other fields of medicine. The far-right column indicates whether a solution is part of a 
“minimum standard” that might be more readily available for wider scaling across other countries, 
healthcare systems or areas of medicine; no formal specific criteria for such a “minimum standard” have 
been defined to date, so the suggestions offered here can only be used to offer some global guidance.  
 
Challenges Possible solutions Specific example(s) Minimum standard  
1. To organize 






• Passive monitoring of falls in 
home environment10,11 
• Passive monitoring using 
mobile health technologies (e.g. 
electronic device typing)12,13 
• Active monitoring (predefined 
tasks using smartphone to 
assess postural tremor or 




 • Online communication • Use online communities to 
support patient empowerment17 
• No 
 • Virtual or physical 
home visits 
• Telemedicine visits by 
neurologists18 
• Interdisciplinary plan including 
home visits19,20 
• Secure video-conferencing18,21 
• Yes 





• Focus on ability to 
adapt and self-manage 
• Education on daily life 
management22,23 
• Yes 
 • Promoting healthy 
lifestyle  
• Healthy diet33 
• Exercise34-36 
• Yes 
 • Support for working 
capacity 
• Education on strategies and 
techniques to counteracting 
symptoms of PD, enabling longer 
workforce participation37 
• Yes 
 • Shared decision making • Shared decision tools for making 
informed choice between 
available options for continuous 
dopaminergic stimulation (deep 
brain stimulation, intraduodenal 
levodopa, apomorphine)38 
• Yes 





3. To manage 
care 
proactively  
• Timely identification of 
specific complications 
that – if left untreated – 
may lead to greater 
handicap and costly 
admissions  
• Active screening for precipitants 
of hospital admission such as 
near-falls 
• Yes 




• Focus on individual 
patient priorities 
• Consider striking difference 
between men and women in 
clinical presentation, treatment 
response and healthcare 
utilisation (e.g., brain surgery for 
PD)24-26 
• Consider racial27-30 or cultural 
differences31,32 
• Yes 
 • Big data and artificial 
intelligence 
• Enable personalized profiling 
and individualized prognostic or 
treatment advice40-42 
• No 





specialisation for all 
professional disciplines 
involved in Parkinson 
care, according to 
evidence-based 
guidelines 
• Training of commonly engaged 
disciplines, such allied health 
professionals or specialised 
nurses43-48 
• Training of less commonly 
recognised disciplines such as 
dentist or pulmonologist49 
• Include nursing home staff and 
clinicians involved in advanced 
care planning (issues at the end-
of-life, palliative care)50,51 
• Yes 
 • Concentration of care 
among trained experts 
(increase case load)  
• Dutch ParkinsonNet approach44 • Yes 
 • Organising peer-to-peer 
networking 
• Implement interprofessional 
education for healthcare 
professionals on evidence-based 
PD practices and working 




• Coordination of care • Employ personal care managers 
to coordinate care for people 
with PD52 
• Yes 
 • Establish links between 
PD-specialists and 
generalists working in 
the community 
• Increase PD-specific knowledge 
amongst general practitioners53 
• Yes 
 • Telemedicine (peer-to-
peer consultations) 
• More accurate clinical decision 
making in the field of acute 
stroke54 
• No 
7. To deliver 
integrated 
care and 
• Breach silos by 
connecting all layers of 
healthcare and bundle 







into model of 
integrated network 
care, both across 
professional disciplines 
and across all echelons 
• Scarce examples available 
outside the field of neurology;56 
models yet to be implemented 





Panel 3. Key elements and outcomes of the Dutch ParkinsonNet model of care.  
 
This model was introduced in 2004 in the Netherlands as an innovative treatment concept for patients 
with PD. Specifically, ParkinsonNet consists of regional community-based networks that encompass a 
restricted number of dedicated allied health therapists who have been trained specifically according to 
evidence-based guidelines. Key elements of the model are described in detail elsewhere44 and are 
summarised below. ParkinsonNet has reached full national coverage in the Netherlands, and currently 
includes 74 regional sub-networks with a total of 3,400 specifically trained healthcare professionals, 
including—among others—physiotherapists, occupational therapists, speech-langue therapists, dieticians, 





• Monodisciplinary—for physiotherapy, speech-language therapy, 
occupational therapy, dietary issues, and nursing home care 
• Multidisciplinary—includes a consensus-based model for regional and 
transmural organisation of multidisciplinary care 
Preferred referral 
 
• Patients and physicians preferentially funnel their referrals towards 
ParkinsonNet experts to increase their caseload (using standardized 
referral forms with referral criteria) 
Education 
 
• Baseline training of participants according to evidence-based guidelines 
(4 days) 
• Learning on the job: increase experience by treating many patients 
• Continuous interaction and information exchange between participants 
through an annual national conference, regional interdisciplinary meetings 





• Informative website (www.ParkinsonNet.nl) 
• Healthcare search engine (www.ParkinsonZorgzoeker.nl) 





• Inclusion of motivated and specifically trained healthcare providers 
only. Every two years a mandatory re-certification is required based on 
quality of care criteria 
Commitment 
 
• Members agree to work according to treatment guidelines and to 
collaborate with other professionals in multidisciplinary teams.  
Transparency about 
quality of services 
and health outcomes 
 
• Outcomes, costs and average caseloads at the regional level published in 




• Various approaches, including use of guidelines for patients, web-based 
communities for patients and web-based informative television program 
for patients (www.ParkinsonTV.nl) 





Panel 4. Expected cost savings from an integrated care approach.  
 
Mechanism 
Improved quality and efficiency of diagnosis (less demand for ancillary testing) 
Fewer outpatient visits: 
- More self-management 
- Healthier lifestyle 
- Optimally timed consultations because of remote monitoring 
- Telemedicine visits instead of physical visits to the hospital 
Fewer inpatient admissions: 
- Prevented disease complications including fractures 
- Fewer medication errors 
Substitution of care: 
- Nurse-led care reduces pressure on more expensive evaluations by movement disorder 
specialists 
Optimal use of integrated multidisciplinary care: 
- Personal care manager ascertains timely referral to specialized professionals 
Seamless organisation of the entire healthcare chain: 







Panel 5. Take-home messages. 
 
• Whenever possible, care should be delivered, where possible within or in proximity to the 
patient’s own home environment, both in terms of monitoring and care delivery.57 
• Educating patients, supports them in self-management, relieves anxiety and alleviates pressure on 
the medical system.4,22,59-65 
• The approach to neurology care should be proactive instead of reactive, thereby preventing 
disease burden and avoiding escalation to more expensive care (including avoidance of unplanned 
admissions).66-72 
• Proactive care can be supported by remote monitoring using sensors and e-diaries, allowing for 
timely detection of medical problems before they derail.99-101  
• Care should be delivered according to each patient’s unique sociodemographic, disease-specific 
and genetic factors, considered in tandem with their personal objectives and goals, following 
personalised “precision” approaches.26-32,40-42,73-81 
• Management of complex neurological conditions such as PD is beyond the expertise of generalists 
alone. There is actually a very important role for generalists in the management of persons with 
PD. In addition, patients benefit from having access to specialised professionals who attract a high 
case load of patients with a particular neurological condition.44-46,50,51,82-89 
• Patients should have easy access to a single point of access (personal care manager) who can 
directly answer simple questions, refer patients to appropriate colleagues, and coordinate the 
multidisciplinary team advice.4,7,52-54,90 
• Care delivery can be optimised further by seamlessly connecting the layers of healthcare and 
bundling all solutions into an integrated network, across both professional disciplines and 






Figure 1. Challenges and strategies for achieving the quadruple aim 
The central goal of healthcare is to reach the Quadruple Aim (central circle). Six important challenges must 
be addressed in order to reach this goal (second circle). We also identify four main strategies that can help 
to address this series of challenges (outer circle). The interplay between these four strategies and six 
challenges in reaching the Quadruple Aim is complex and multifaceted. For example, patient 
empowerment helps to achieve a more personalized care delivery, facilitates care delivery close to home 
and makes care timelier, with an improved patient experience, improved health outcomes and reduced 
costs as important results. Similarly, professional empowerment ascertains that patients receive 
appropriate care, but well-trained clinicians are likely also better able to deploy precision medicine 

















Figure 2. The “home-hub-and-spoke” model  
 
 
A. Illustration of how a centre of expertise (the hub – services shown in blue) can be coupled to a single 
spoke (services shown in red), consisting of a neighbouring community hospital (where regional care is 
delivered by Parkinson’s specialist doctors), a Parkinson nurse (acting as personal care manager) and 
regional community-based professionals. Specific services offered include: (1) remote home-based 
monitoring and self-management by patients; (2) personalized care management; (3) a specialised 
regional care team, including facilities for inpatient and outpatient rehabilitation, and nursing homes with 
trained staff; (4) remote peer-to-peer support offered by a centre of expertise, with the option to 
physically see patients with specific health issues (complex or expensive ancillary testing; advanced 
treatments); and (5) centralised educational and supportive resources for both patients and professionals 
(services shown in green). B. One centre of expertise can support many surrounding community hospitals 
(multiple spokes). The Parkinson nurses working in the various spokes could collectively form a virtual 







Supplement A. Barriers to reaching the Quadruple Aim. 
 
Several important barriers in today’s healthcare that hamper us from reaching the Quadruple Aim. These are visible 
even in high-income countries such as the U.S. or United Kingdom, with even worse conditions in lower income 
countries.31,103 The inadequacies of care exist worldwide in spite of different models of healthcare and differences in 
funding. Together, these shortcomings lead to avoidable disability and unnecessarily high costs. 
 
Fragmentation of care: 
• Poor interdisciplinary collaboration and disconnected monodisciplinary therapies 
• Numerous barriers between different healthcare settings 
• Difficult, delayed and greatly variable access to services and therapies29,30 
• Traditional hierarchical approach 
Reactive approach: 
• Focusing on repairing problems after they have arisen * 
Inability to manage complex problems: 
• Lack of disease-specific expertise among many clinicians 
Predominantly physician-driven care: 
• Primary focus on medical management (pharmacotherapy, neurosurgery), with less attention to non-pharmacological 
interventions, and even less to lifestyle or social issues 
• Lack of patient involvement in decision making 
Emphasis on institutionalized care: 
• Outpatient visits inadequate reflection of problems in daily living57 
• Inpatient visits often associated with poor services and outcomes66,104 
Disease-centred care: 
• One-size-fits-all approach 
• Emphasis on protocols that are informed by averaged group results from trials. 
 
* For example, in the UK, unplanned hospital admissions among persons with PD are often related to falls and to 
urinary tract infections, some of which may be anticipated and proactively managed. In the U.S., 88% of personal 
healthcare expenditures are devoted to hospital or nursing home care, whereas only 7% is spent on ambulatory 






Supplement B. Digitised health as supportive tool to enable integrated care. 
 
Many of the integrated care solutions proposed here can be supported by new developments in the field of digitised 
health and technology-enabled “individualization”, not as a goal in its own right, but as a supportive tool to make the 
proposed interventions more effective, customer-friendly, timely and cheaper. We distinguish several important digital 
enablers: 
• Ambulatory real-life monitoring, using sensors–worn on the body,13,16 intelligent domotics 
incorporated into the patient’s house (i.e. smart homes with embedded sensors, for detecting e.g. 
daily mobility, or falls)107,108 or analysing the usage of common appliances such keyboard typing 
behaviour12. These approaches hold great promise to assess patients in their own environment. 
Specific symptoms such as tremor seem very “measurable”, but others with a more complex 
symptomatology such as dyskinesias in PD, are less straightforward to capture. Monitoring can be 
passive (occurring in the background) or active (asking patients to complete scheduled tasks at fixed 
intervals). Specific examples of both types of monitoring are presented in Panel 2. Many issues 
remain, including the need to optimise compliance with technical devices, particularly among older 
people and those with cognitive impairment; and having a readily available helpdesk strategy.11 
Patients themselves are open to self-monitoring, although a balance must be struck between the 
burden (time and energy spent) and benefits (great knowledge and self-efficacy).109 Another 
challenge is the need to validate the sensor’s algorithms not just in the laboratory, but also in real-
life settings where patients can behave very differently.110 Finally, sensors are likely most helpful to 
monitor motor symptoms, but the many non-motor symptoms (e.g. cognitive decline, autonomic 
failure) are at least as important to patients.111 Development of a reliable e-diary could serve this 
purpose.112  
• Online communication platforms, enabling easy patient access to care, and facilitating 
interdisciplinary communication and collaboration between different professionals, and between 
patients and professionals.17,21 This includes the ability to easily exchange relevant medical 
information and to synchronize the patient’s healthcare plan, to promote communication between 
patients and their healthcare team and to facilitate the exchange of knowledge. 
• New developments in telemedicine may allow professionals to pay a virtual home visit via secure 
videoconferencing.21 This is important where travel distances are long or travel burden is high or 
because driving behaviour has become unsafe for people with neurological disorders such as PD.113 
A next step is to develop this telemedicine approach for other disciplines, such as specialised nurses 
or allied health therapists, thus creating a concept of “tele-rehabilitation”. Recent work has shown 
the feasibility of this approach for people with stroke, showing that activity-based training was as 
effective when delivered via telemedicine as compared to an in-clinic program.114 Safety issues must 
be addressed, e.g. the risk of falling when physiotherapists deliver balance training or exercise 
programs remotely. Early studies formally assessing the utility of home visits from the 
multidisciplinary team have showed promise.19 
• Big data and artificial intelligence, for personalized profiling and individualized prognostic or 
treatment advice.40,41,90 
 
Current evidence on the role of digital health in the care for patients with PD 
Prior research mostly focused on developing reliable algorithms, testing their face validity relative to current clinical 
measures, or demonstrating the feasibility of introducing technological innovations to a typically elderly population, 
including persons with cognitive decline, reduced dexterity (hampering adequate manipulation of devices) or simply 
lack of appetite for technological innovations.11,110,115,116 Small pilot studies using remote monitoring with wearable 
sensors suggested some positive effects on clinical decision-making and reasonable correlations with motor symptoms 
of PD.99-101 The costs of many technological solutions are likely low (certainly with bring-your-own-device solutions, 
such as a person’s own smartphone), but whether these upfront investments are outweighed by subsequent health 
benefits or cost savings remains unclear. One study provided class III evidence that a telemedicine approach–offering 
neurology services via video conferences–was feasible and resulted in health outcomes comparable to regular 
outpatient visits, but with greater efficiency and convenience for patients (no time wasted on traveling or waiting 
rooms).18 How this translated into possible cost savings was unclear. Further work remains needed to establish the 
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cost-effectiveness of the whole gamut of digital health solutions. Furthermore, reliable algorithms must be developed 
that can trigger an intervention by healthcare professionals when a dangerous situation or high-risk trait is detected 
automatically. This issue was recently addressed in a study on passive monitoring of falls that occurred in the own 
home environment of persons with PD.11 In that study, fall events were automatically detected by a wearable sensor, 
and all falls were confirmed by an immediate follow-up call (i.e. there were no false-positive events). The feasibility 
of that approach is conditional on the availability of support personnel to follow-up with an immediate call, aiming to 
send staff to the patients’ home to assist those unable to rise from the floor independently. Future developments could 
focus on developing reliable algorithms for body-worn or domestic sensors to detect other relevant events that are 
difficult to capture during brief outpatient visits, such as complex response fluctuations to dopaminergic medication or 
gradual decreases in physical activity. The validity of such algorithms must be demonstrated not just in controlled 
laboratory conditions, but also in daily-living cicrumstances.110 Importantly, before replacing components of usual 
care, it is essential that digital innovations are studied as carefully designed add-on interventions in real-life settings. 
Finally, we should point out that the transition to telemedicine-based solutions will take time, even for seemingly 
straightforward errands such as refilling prescription medication, which in countries like China currently requires 





Supplement C. The role of Parkinson nurses in care management. 
 
Nurses can facilitate the actual implementation of the management plan which can prove particularly challenging to 
people with PD who are affected by dysexecutive problems. Evidence suggests that most recommendations made by a 
multidisciplinary team within an expert centre were never followed up in the community,117 which may have resulted 
from the lack of a care manager who was responsible for long-term follow-up. Conversely, compliance with treatment 
recommendations–made after home visits by a multidisciplinary team–was much better when a Parkinson nurse 
followed up by telephone several weeks after the home visit.19 Furthermore, patients in the U.S. appear to underutilize 
rehabilitation services, particularly when they are not followed-up by a neurologist.29 Having access to a personal care 
manager could be a solution for this issue. 
 
Research in the field of dementia has shown that the quality of care improves and that costs are reduced when patients 
have access to a personal care manager.8 There is less research experience in PD, although a recent controlled study 
showed that persons with PD whose care was guided through the telephone by Parkinson nurses were more likely to 
be managed according to established quality indicators.118 Except for an effect on depression, this care management 
did not translate into tangible health benefits (most patient-centred outcomes were no different from a control group 




Supplement D. Economic feasibility in low-income, low-middle and higher-income countries. 
 
It is uncertain whether the approach proposed here will be economically feasible in low-income, low-middle income 
countries or even higher income countries. We should emphasise that the primary aim is not to save costs, but to 
improve the quality of care, thereby improving patient outcomes and quality of life. However, some concurrent cost 
savings can be expected. Prior work showed that a multidisciplinary network approach was cost-effective in the 
Netherlands, where the costs of building and maintaining a professional network were outweighed by subsequent cost 
savings, resulting from greater efficiency of care, prevented disease complications and fewer inpatient admissions.93 
While it is uncertain whether this experience can be translated to other countries, it is conceivable that even greater 
cost savings could arise in areas where hospitalization rates are higher than those in the Netherlands.93 This includes 
the US, where many patients have no access to a neurologist, and this is associated with a higher rate of inpatient 
admissions.119,120 Hence, the potential benefits of an integrated and patient-centred care system are potentially even 
higher in countries where care is currently les well organised compared to the Netherlands. Importantly, although we 
present the integrated and patient-centred care solution here to address the demands of major neurological disorders, 
we–and others121,122–feel that a comparable approach will also benefit other major societal threats, such as the burden 
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